Medication approval journey
atomoxetine (Strattera)
Approved for ADHD in pediatric patients 6 and older and adults
Before changing anything
Stopping abruptly can be dangerous — never do it without medical supervision
Clonidine and guanfacine must not be stopped abruptly — rebound high blood pressure is a real risk. Any change should be prescriber-supervised.
How long the trials actually ran
We could not establish a longest trial length for atomoxetine. That is a gap in what we can show you — not evidence that the trials ran long.
The label carries a clinical studies section describing the trials the approval rested on.
The gap between how long the trials ran and how long people actually take these medications is the single most important thing on this page. It is not evidence that longer use is unsafe or ineffective. It is evidence that longer use was not what got tested.
The boxed warning
The strongest warning the FDA puts on a label, reproduced word for word — not our summary of it.
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER All atomoxetine-treated pediatric patients 6 years of age or older should be monitored and observed closely for suicidal thoughts and behavior, clinical worsening, or unusual changes in behavior, especially during the initial months of therapy or at times of dosage changes. Families and caregivers should be advised of the need for close observation and communication with the health care provider. Consider stopping atomoxetine in patients who experience emergent suicidal thoughts and behavior [see Warnings and Precautions (5.1) ]. Atomoxetine increased the risk of suicidal ideation in pediatric patients aged 6 years of age and older with attention-deficit/hyperactivity disorder (ADHD) in short-term studies. WARNING: SUICIDAL THOUGHTS AND BEHAVIORS IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER See full prescribing information for complete boxed warning. All atomoxetine-treated pediatric patients 6 years of age or older should be monitored and observed closely for suicidal thoughts and behavior, clinical worsening, or unusual changes in behavior, especially during the initial months of therapy or at times of dosage changes ( 5.1 ) Consider stopping atomoxetine in patients who experience emergent suicidal thoughts and behavior ( 5.1 ) Atomoxetine increased the risk of suicidal ideation in pediatric patients aged 6 years of age and older with attention-deficit/hyperactivity disorder (ADHD) in short-term studies ( 5.1 )
FDA label effective August 14, 2026 — read the full label on DailyMed
How many Americans take atomoxetine
Survey-based federal estimates, published with a lag of about two years. They count prescriptions filled, not outcomes.
- 4,208,253
- prescriptions in the United States (2024)
- 948,465
- people filling them (2024)
Prescriptions are up 64% since 2014. Whatever you decide about atomoxetine, you are deciding alongside about 948,465 other people this year.
Source: ClinCalc DrugStats (Medical Expenditure Panel Survey (MEPS), Agency for Healthcare Research and Quality), CC BY-SA 4.0, release 2026.08.
What people report to the FDA about atomoxetine
Read this before the numbers.
Anyone can file an adverse event report — patients, doctors, manufacturers — and nobody verifies that the drug caused what was reported. There is no denominator: tens of millions of prescriptions generate reports at an unknowable rate, and reporting rises with news coverage, not necessarily with harm. Counts below are report volumes, not rates, and cannot be compared between drugs. The FDA itself says not to use this data to make medical decisions — we show it because you deserve to see what is in the public record, with its limits stated plainly.
- 26,970
- reports mentioning atomoxetine, all time
- 11,821
- filed as serious (a report-level flag covering every drug and outcome in the report)
Most-reported reactions
- Drug ineffective2,955
- Nausea2,251
- Fatigue2,246
- Headache1,843
- Vomiting1,815
- Off label use1,799
- Dizziness1,708
- Insomnia1,618
- Depression1,478
- Somnolence1,461
“Drug ineffective” ranking this high is worth noticing: a report of not being helped counts as an adverse event too, and people file them in large numbers.
Source: FDA Adverse Event Reporting System (FAERS), via openFDA, data through 2026-07-30.
Known interactions, from the label
The FDA label’s interactions section, verbatim. A pharmacist checking your actual medication list beats any published list — including this one.
Read the label’s interactions section
7 DRUG INTERACTIONS See Table 8 for clinically significant drug interactions with atomoxetine and other drugs. Table 8: Clinically Significant Drug Interactions with Atomoxetine Capsules and Other Drugs Monoamine Oxidase Inhibitors (MAOIs) Prevention or Management Atomoxetine is contraindicated in patients taking MAOIs, including MAOIs such as linezolid or intravenous methylene blue, or in patients who stopped an MAOI within 14 days. Mechanism and Clinical Effect(s) As with other drugs affecting brain monoamine concentrations, there have been reports of serious, sometimes fatal reactions (hyperthermia, rigidity, myoclonus, autonomic instability with fluctuations of vital signs, extreme agitation progressing to delirium/coma) with concomitant use of atomoxetine and an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Strong CYP2D6 Inhibitors Prevention or Management With concomitant use of atomoxetine and a strong CYP2D6 inhibitor, increase the titration interval [see Dosage and Administration (2.5) and Clinical Pharmacology (12.3) ]. Mechanism and Clinical Effect(s) Atomoxetine is a CYP2D6 substrate. The concomitant use of atomoxetine and a strong CYP2D6 inhibitor increases atomoxetine exposure [see Clinical Pharmacology (12.3) ] . Antihypertensive Drugs Prevention or Management Increase the frequency of monitoring blood pressure and adjust atomoxetine dosage as clinically appropriate. Mechanism and Clinical Effect(s) Because of increased risk of increased blood pressure, atomoxetine should be used cautiously with antihypertensive drugs, other drugs that increase blood pressure or pressor drugs (e.g., dopamine, dobutamine). Albuterol or Other Beta2 Agonists Prevention or Management Increase the frequency of monitoring blood pressure and heart rate and adjust atomoxetine dosage as clinically appropriate. Mechanism and Clinical Effect(s) Systemically administered albuterol (e.g., oral) can be potentiated by atomoxetine, resulting in increases in heart rate and blood pressure. [see Clinical Pharmacology (12.3) ]. Monoamine Oxidase Inhibitors: Concomitant use contraindicated. ( 4 , 7 ) Strong CYP2D6 Inhibitors: With concomitant use of atomoxetine and strong CYP2D6 inhibitors, increase the titration intervals. ( 7 ) Antihypertensives: Increase the frequency of monitoring blood pressure and adjust atomoxetine dosage as clinically appropriate. ( 7 ) Albuterol (or other beta2 agonists): Increase the frequency of monitoring blood pressure and heart rate. ( 7 )
FDA label for atomoxetine, effective August 14, 2026 — DailyMed.
Who pays for atomoxetine
Two claims datasets and one survey, covering different populations with different instruments — they cannot be reconciled by arithmetic, and where their sum crowds the all-payer estimate, that is a finding about the estimates rather than a percentage.
- Medicare Part D
- 66,109 beneficiaries filled 327,343 claims in 2024 — 24,096 aged 65 and over, and 42,013 under 65. The under-65 group is not a picture of ordinary working-age adults: Medicare before 65 means the disabled and dual-eligible population — among the sickest, highest-need people in the program — and reading their utilization as typical adult use would be a category error.
- Medicaid
- At least 1,651,014 prescriptions in 2024 — a floor, because 66 of 553 national data rows are suppressed for privacy and contribute zero. Medicaid covers more children than any insurer in the country and publishes no age split — how much of this number is pediatric use is not knowable from public data.
- All payers (survey estimate)
- The MEPS-based estimate above puts the whole country at 4,208,253 prescriptions and 948,465 people in 2024. Subtracting the public programs from it would produce a number for everyone else — and we do not print that number, because subtracting a survey from claims counts manufactures precision that does not exist.
- The population nobody counts
- The commercially insured working-age adult — statistically, the likeliest person to be reading this page — is the one population with no public per-drug count anywhere. Private claims data exists and is sold, but nothing a patient can check is published. For children the record is thinner still: no public source counts pediatric use of atomoxetine specifically; the closest the public record comes is condition-level treatment rates for children, which we have traced for one condition in how childhood ADHD got counted.
Sources: Medicare Part D Prescribers — by Geography and Drug, data.cms.gov, National rows, data year 2024 (published with ~17-month lag). Medicaid State Drug Utilization Data 2024, data.medicaid.gov, national aggregate rows. Retrieved 2026-09-01.
The approval, step by step
Step 1
What the approval was actually based on
Which studies did the FDA rely on, how long did they run, and who was in them?
The effectiveness of STRATTERA in the treatment of ADHD was established in four randomized, double-blind, placebo-controlled studies of pediatric patients 6 to 18 years of age (Studies 1, 2, 3, and 4). In these studies, approximately one-third of the patients met DSM-IV criteria for inattentive subtype and two-thirds met criteria for both inattentive and hyperactive/impulsive subtypes...
FDA-approved labelling, 14 CLINICAL STUDIES — read the label on DailyMed
Our reading
The first non-stimulant approved for ADHD, and marketed hard on exactly that distinction. The acute pediatric trials ran six to nine weeks, adult trials about ten, with a longer maintenance study following. Two label facts arrived after approval and deserve to be read together with it: a boxed warning about suicidal ideation in children and adolescents was added in 2005, three years in — and the brand itself was later discontinued, so every Strattera prescription filled today is a generic riding on this application's evidence.
Step 2
The approval
When was it approved, under what application, and by whose review?
- Approved
- November 26, 2002
- Application
- NDA021411
- Review
- STANDARD
- Original sponsor
- Eli Lilly and Company
- Holds it now
- Eli Lilly and Company
- Label submissions since
- 37
Source: openFDA Drugs@FDA, original application ORIG-1
Step 3
What was added after it was on the market
Which warnings arrived only after millions of people were already taking it?
We have not recorded a post-approval change to the atomoxetine label. That is the state of our record, not a finding that nothing was ever added.
Step 4
What independent research has found since
What has been learned by people who were not selling it?
We have not yet added independent post-approval research on atomoxetine to the evidence library. Absence here means we have not covered it, not that none exists.
Step 5
What still is not known
Which questions you might reasonably have has nobody answered yet?
- The suicidal-ideation boxed warning arrived in 2005, three years after approval. What did the pivotal trials measure that missed it?
- Non-stimulant is a safety claim as much as a mechanism. Compared head-to-head with stimulants on outcomes, what is known?
- Acute trials of six to ten weeks, for a condition treated for years — the standard question, no better answered here.
Deciding about atomoxetine?
- 12 questions to ask before starting a psychiatric medication — each with the study behind it
- Already on it? The 10-question annual review — including the honest case for staying
- How long every drug here was tested before approval — one chart, all medications
Open atomoxetine (Strattera) in Resolv
The app has the full approval journey, the resources behind it, and people working through the same questions.
